Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL690839 | 0.79 | SMN1; SMN2 (0.48) | SMN1; SMN2ZDHHC7CA1CA2CA14 | |
| SCHEMBL330404 | 0.79 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL3321641 | 0.79 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL3277859 | 0.77 | ALDH1A1 (0.39) | SMN1; SMN2CA1CA2CA14CA12 | |
| SCHEMBL10782791 | 0.75 | SMN1; SMN2 (0.40) | SMN1; SMN2CA1CA2CA14CA12 | |
| SCHEMBL11838499 | 0.74 | DGAT1 (0.41) | SMN1; SMN2ZDHHC7CA1CA2CA14 | |
| SCHEMBL9130100 | 0.72 | — | — | |
| SCHEMBL1512190 | 0.72 | — | — | |
| SCHEMBL80876 | 0.71 | HSP90AA1 (0.44) | SMN1; SMN2CA1CA2CA14CA12 | |
| SCHEMBL11287379 | 0.70 | SMN1; SMN2 (0.40) | SMN1; SMN2ZDHHC7CA1CA2CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298314-A1 | NOVEL JNK INHIBITORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20100298314-A1 | NOVEL JNK INHIBITORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | disclosed |
| WO-2008082490-A2 | NOVEL JNK INHIBITORS | SCHERING CORPORATION (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298314-A1 | NOVEL JNK INHIBITORS | MAPK1, MAPKAPK2, MAP4K2 | SMN1; SMN2 2617/4885ZDHHC7 1483/4885CA1 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.